|
 |
Nekomercijalni |
|
|
Zaštićeni nazivi su indikativni i sastav ekscipijensa može biti različit ovisno o državi i laboratorijima
|
|
Accofil |
Belgija, Hrvatska, Njemačka, Velika Britanija |
|
Duperan |
Čile |
|
Filgen |
Argentina, Čile |
|
Foltran |
Čile |
|
Granulokine |
Brazil, Grčka, Italija |
|
Hebervital |
Kolumbija |
|
Inmunef |
Kolumbija, Meksiko |
|
Leucosos |
Kolumbija |
|
Lioplim |
Čile |
|
Neupogen |
Australija, Austrija, Belgija, Čile, Danska, Egipat, Ekvador, Finska, Francuska, Iran, Irska, Kanada, Kolumbija, Luksemburg, Malezija, Maroko, Meksiko, Nizozemska, Njemačka, Norveška, novi Zeland, Poljska, Portugal, S A D, Saudijska Arabija, Slovenija, Španjolska, Švedska, Švicarska, Turska, Ujedinjeni Arapski Emirati, Velika Britanija, Venecuela |
|
Neutromax |
Argentina |
|
Neutropine |
Argentina |
|
Nivestim |
Belgija, Francuska, Nizozemska, Njemačka, Norveška, Velika Britanija |
|
Ratiograstim |
Austrija, Njemačka, Švedska, Velika Britanija |
|
Tevagrastim |
Belgija, Brazil, Čile, Hrvatska, Nizozemska, Njemačka, Norveška, Španjolska, Švedska, Švicarska, Velika Britanija |
|
|
 |
 |
Bibliografija : Filgrastim |
|
|
Vrsta |
Publikacija |
| 99 |
Časopis |
Trissel LA, Martinez JF.
Compatibility of aztreonam with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 1086-1090. |
| 104 |
Časopis |
Hall PD, Yui D, Lyons S, Bosso JA.
Compatibility of filgrastim with selected antimicrobial drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 185-189. |
| 182 |
Časopis |
Trissel LA, Gilbert DL, Martinez JF.
Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 56-60. |
| 244 |
Časopis |
Trissel LA, Martinez JF.
Compatibility of filgrastim with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1907-1913. |
| 2269 |
Časopis |
Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H.
Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551. |
| 3128 |
Laboratorija |
Mitomycine (Amétycine®) - Résumé Caractéristiques du Produit
Prostrakan 2013 |
| 3249 |
Časopis |
Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB.
Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2011 ; 68: 2163-2169. |
| 3256 |
Časopis |
Burnett B, Radic I.
Stability of Hospira filgrastim following changes to thermal and photic storage conditions.
EJHP 2011 ; 17, 5: 49-56. |
| 3474 |
Laboratorija |
Fluorouracil - Summary of Product Characteristics
Accord Healthcare Limited 2009 |
| 3618 |
Laboratorija |
Filgrastim (Neupogen®) - Summary of Product Characteristics
Amgen 2014 |
| 3828 |
Plakat |
Thabit A.K, Hamada Y, Nicolau D.P.
Ceftozolane/tazobactam physical compatibility during simulated Y-site administration.
ASHP Midyear 2015 |
| 3829 |
Plakat |
So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L.
Compatibility of isavunazonium sulfate during simulated Y-site administration.
ASHP Midyear 2015 |
| 4055 |
Časopis |
Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D.
Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2018 , 75, 1:36-44 |
| 4380 |
Laboratorija |
Posaconazole (Noxafil®) - Summary of Product Characteristics
Merck Sharp & Dohme Limited 2019 |
| 4471 |
Laboratorija |
Amétycine 10 mg poudre pour solution injectable - Résumé des caractéristiques du produit - Oct 10, 2019
Kyowa Kirin Pharma 2019 |
| 4521 |
Časopis |
Polo C, D’Huart E, Lesperlette G, Vigneron J, Meyer F, Demoré B.
Compatibility of injectable posaconazole with drugs commonly used in a hematology care unit.
Pharmaceutical Technology in Hospital Pharmacy 2020 |
| 4650 |
Laboratorija |
Ceftobiprole (Zevtera 500 mg powder for concentrate for solution for infusion.) Summary of Product Characteristics, Advanz Pharma updated 4 aug 2021.
Advanz Pharma 2021 |
|
|
